Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$25.13M, compared with -$29.86M a year earlier.
Context
- Net debt amounted to 98.9% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +15.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (31.63M) USD
- Year-over-year change
- -70.7%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31.63M) | -70.7% |
| FY2024 | 2024-12-31 | (18.53M) | +3.1% |
| FY2023 | 2023-12-31 | (19.13M) | +4.3% |
| FY2022 | 2022-12-31 | (19.99M) | -248.2% |
| FY2021 | 2021-12-31 | (5.74M) | — |
Net Debt vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 net debt of -$25.13M is the 4th highest of the 11 companies compared; the peer median is -$33.24M.
- Its year-over-year change of +15.9% is the 7th highest of 11, against a peer median of +41.1%.
- Net debt amounts to 98.9% of total assets for NVCT, versus a peer median of 17.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.68B | +11687.6% | — | 1.7% | |
| Mar 2026 | $214.47M | +241.0% | — | 45.4% | |
| Jun 2026 | -$6.46M | +96.6% | — | 0.9% | |
| Mar 2026 | -$25.13M | +15.9% | — | 98.9% | |
| Mar 2026 | -$30.01M | +72.2% | — | 13.8% | |
| Mar 2026 | -$30.26M | +40.8% | — | 2.9% | |
| Mar 2026 | -$36.22M | +41.3% | — | 89.2% | |
| Mar 2026 | -$45.38M | -30.9% | — | 22.1% | |
| Mar 2026 | -$53.1M | -15.1% | — | 12.2% | |
| Mar 2026 | -$78.21M | -426.3% | — | 81.6% | |
| Mar 2026 | -$80.08M | -96.4% | — | 35.2% | |
| Peer median (excluding NVCT) | -$33.24M | +41.1% | — | 17.9% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.